Decellularized extracellular matrix-based disease models for drug screening.

Area of Science:

• Biomaterials Science
• Drug Discovery
• Regenerative Medicine

Background:

• * In vitro drug screening aims to mimic in vivo cellular environments for accurate drug response prediction.
• * Decellularized extracellular matrix (dECM) offers a biologically relevant scaffold, recapitulating in vivo conditions for disease modeling.
• * ECM components are crucial for cellular function and disease progression, making dECM ideal for disease models.

Purpose of the Study:

• * To review advancements in using dECM-based biomaterials for creating cell models for drug screening.
• * To explore the potential of dECM in disease modeling for various conditions.
• * To summarize challenges and future directions for dECM in drug assessment and personalized medicine.

Main Methods:

• * Delineation of ECM component functionalities and their role in disease models.
• * Elucidation of decellularization techniques and dECM substrate fabrication for cell models.
• * Review of research employing dECM models for drug screening in various diseases (cancer, heart, liver, lung, bone).

Main Results:

• * dECM-based materials provide a more authentic cellular environment compared to traditional methods.
• * dECM models have demonstrated utility in drug screening for diverse pathologies.
• * Identified bottlenecks and future research avenues for dECM in drug screening and personalized medicine.

Conclusions:

• * dECM biomaterials represent a significant advancement in creating physiologically relevant cell models for drug screening.
• * The application of dECM models holds substantial promise for enhancing drug discovery and enabling personalized therapies.
• * Continued research into dECM fabrication and application will accelerate its integration into clinical drug assessment.